公开(公告)号：US20180258130A1

公开(公告)日：2018-09-13

申请号：US15981813

申请日：2018-05-16

Applicant: IDENIX PHARMACEUTICALS LLC

Inventor： Benjamin Alexander MAYES ,  Adel M. MOUSSA ,  Alistair James STEWART ,  Gilles GOSSELIN ,  Christophe Claude PARSY ,  François-René ALEXANDRE ,  Jean-François GRIFFON ,  Dominique SURLERAUX ,  Cyril B. DOUSSON ,  Claire PIERRA ,  Houcine RAHALI

IPC: C07H19/20 ,  C07H19/10 ,  A61K31/403 ,  C07H19/16 ,  A61K38/55 ,  A61K38/21 ,  A61K31/7056 ,  A61K31/708 ,  A61K31/7076 ,  A61K45/06 ,  A61K31/7072 ,  A61K31/4709 ,  A61K31/497

Abstract: Provided herein are compounds, compositions and methods for the treatment of liver disease and conditions, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.

公开(公告)号：US20170088577A1

公开(公告)日：2017-03-30

申请号：US15379415

申请日：2016-12-14

Applicant: Idenix Pharmaceuticals LLC ,  Universita degli Studi di Cagliari ,  Centre National De La Recherche Scientifique ,  Universite de Montpellier

Inventor： Richard STORER ,  Gilles GOSSELIN ,  Jean-Pierre SOMMADOSSI ,  Paolo LACOLLA

IPC: C07H19/16 ,  A61K38/21 ,  A61K9/20 ,  A61K9/48 ,  C07H19/056 ,  A61K31/7068 ,  A61K31/7076 ,  A61K31/7072 ,  A61K31/7056 ,  A61K31/708 ,  A61K45/06 ,  C07H19/06

CPC classification number: C07H19/16 ,  A61K9/20 ,  A61K9/48 ,  A61K31/675 ,  A61K31/7056 ,  A61K31/7068 ,  A61K31/7072 ,  A61K31/7076 ,  A61K31/708 ,  A61K38/21 ,  A61K38/212 ,  A61K45/06 ,  A61K47/60 ,  C07H19/00 ,  C07H19/04 ,  C07H19/048 ,  C07H19/056 ,  C07H19/06 ,  C07H19/22 ,  A61K2300/00

Abstract: 2′ and/or 3′ prodrugs of 1′, 2′, 3′ or 4′-branchednucleosides, and their pharmaceutically acceptable salts and derivatives are described. These prodrugs are useful in the prevention and treatment of Flaviviridae infections, including HCV infection, and other related conditions. Compounds and compositions of the prodrugs of the present invention are described. Methods and uses are also provided that include the administration of an effective amount of the prodrugs of the present invention, or their pharmaceutically acceptable salts or derivatives. These drugs may optionally be administered in combination or alteration with further anti-viral agents to prevent or treat Flaviviridae infections and other related conditions.

公开(公告)号：US20170044205A1

公开(公告)日：2017-02-16

申请号：US15304506

申请日：2015-04-16

Applicant: IDENIX PHARMACEUTICALS LLC

Inventor： David DUKHAN ,  Cyril B. DOUSSON ,  Gilles GOSSELIN ,  Jean-Laurent PAPARIN ,  Guillaume BRANDT ,  Rachid RAHALI ,  Aurelien SALANSON ,  François-René ALEXANDRE

IPC: C07H19/20 ,  A61K31/7068 ,  C07H19/10 ,  A61K31/7072 ,  A61K45/06 ,  A61K31/7076

CPC classification number: C07H19/20 ,  A61K31/7052 ,  A61K31/706 ,  A61K31/7064 ,  A61K31/7068 ,  A61K31/7072 ,  A61K31/7076 ,  A61K31/708 ,  A61K45/06 ,  C07H19/10 ,  C07H19/11

Abstract: Provided herein are compounds, compositions and methods for the treatment of Flaviviridae infections, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents. In certain embodiments, the compounds are 3′-substituted methyl or alkynyl nucleosides of Formula I: (I); or a pharmaceutically acceptable salt, solvate, stereoisomeric form, tautomeric form or polymorphic form thereof, wherein Base, PD, RA, RB1, RB2, RC and Z are as defined herein.

Abstract translation: 本文提供了用于治疗黄病毒科感染（包括HCV感染）的化合物，组合物和方法。 在某些实施方案中，公开了核苷衍生物的化合物和组合物，其可以单独施用或与其它抗病毒剂组合施用。 在某些实施方案中，化合物是式I的3'-取代的甲基或炔基核苷：（I）; 或其药学上可接受的盐，溶剂化物，立体异构形式，互变异构形式或其多晶型形式，其中碱，PD，RA，RB1，RB2，RC和Z如本文所定义。

公开(公告)号：US20160002281A1

公开(公告)日：2016-01-07

申请号：US14856462

申请日：2015-09-16

Applicant: Idenix Pharmaceuticals LLC

Inventor： Benjamin Alexander MAYES ,  Adel M. MOUSSA ,  Alistair James STEWART ,  Gilles GOSSELIN ,  Christophe Claude PARSY ,  François-René ALEXANDRE ,  Jean-François GRIFFON ,  Dominique SURLERAUX ,  Cyril B. DOUSSON ,  Claire PIERRA ,  Houcine RAHALI

IPC: C07H19/20 ,  C07H19/10

CPC classification number: C07H19/20 ,  A61K31/403 ,  A61K31/4709 ,  A61K31/497 ,  A61K31/7056 ,  A61K31/7072 ,  A61K31/7076 ,  A61K31/708 ,  A61K38/21 ,  A61K38/55 ,  A61K45/06 ,  C07H19/10 ,  C07H19/16 ,  A61K2300/00

Abstract: Provided herein are compounds, compositions and methods for the treatment of liver disease and conditions, including HCV infections. In certain embodiments, compounds and compositions of nucleoside derivatives are disclosed, which can be administered either alone or in combination with other anti-viral agents.